Appeal to the Autism
Community
Dear Parents, Grandparents and Friends of Children with autism,
The possibility that Thimerosal and MMR vaccination play any role in
Regressive Autism has been denied and ruled out by a special committee of
the Institute of Medicine at a meeting on February 9, 2004.
In their report, the committee members essentially said that the epidemic of
regressive autism we are facing is due to other factors and that further
research into a vaccine link should not be encouraged nor supported.
I hope that you will agree to endorse and second my request to President
Fineberg of the IOM to retract the report in question, form a new committee
under a new Chairperson and reconvene meetings on the subject.
I also ask you to please convince your groups and associations to use their
strong influence to support this effort.
Your help is urgently needed.
You can encourage research in the environmental, biological and immune
causes of Regressive Autism or you can do nothing and watch as we lose
another generation.
Thank you.
F. Edward Yazbak, MD, FAAP
TL Autism Research
70 Viewcrest Drive
Falmouth, Massachusetts 02540
Tel (508) 540 5060 Fax (508) 457 9814
________________________________
His Letter:
F. Edward Yazbak, MD,
FAAP
TL Autism Research
70 Viewcrest Drive
Falmouth, Massachusetts 02540
Tel (508) 540 5060 Fax (508) 457 9814
Harvey
V. Fineberg, MD, PhD
President
Institute of Medicine
500 Fifth Street NW
Washington DC 20001
May 11, 2005
Dear President Fineberg,
I respectfully request that you
o
Withdraw
the report of the Immunization Safety Review Committee Meeting 9 of February
9, 2004
o
Form a
new committee under a new chairman all of whom should be impartial experts
independent of influence of Government and pharmaceutical companies.
o
Reconvene a meeting on vaccines and autism as soon as possible and ensure
that all independent research is considered.
I base my request on the attached information.
You and only you, Dr. Fineberg can reverse the damage that has been done to
thousands of children and their families by the unfortunate, biased and
scientifically flawed report of the committee.
Respectfully,
_____________________
F. Edward Yazbak, MD
F. Edward Yazbak, MD, FAAP
TL Autism Research
Falmouth, Massachusetts 02540
Withdraw the Report
o
The
Institute of Medicine should withdraw the report of the February 9, 2004
Immunization Safety Review
Committee Meeting 9: Vaccines and Autism
o
A new
Immunization Safety Review Committee should be formed under new chairmanship
o
A
meeting of the committee should be convened as soon as possible
_________________________
Background Information
A. IOM Committee conclusions are based on research and information
that justify one of the following classifications:
1. No evidence bearing on a causal relation.
2. The evidence is inadequate to accept or reject a causal relation.
3. The evidence favors rejection of a causal relation.
4. The evidence favors acceptance of a causal relation.
5. The evidence establishes a causal relation.
B. Between school years 2002-03 and 2003-04, the number of children with
autism and ASD attending school in the United States increased by 18.18% for
age 6-21 from 118,603 to 140,922 and by 19.5% for age 3-5 from 19,017 to
22,724. (1-4)
C. HHS, CDC and AAP have conceded in 2004 that 1 in 166 children in the
United States are diagnosed with an autism spectrum disorder. (5)
D. On January 15, 2004, Congressman Weldon wrote to CDC Director Dr. Julie
L. Gerberding (6): “I am writing to ask that you post-pone the February 9,
2004, Institute of Medicine (IOM) Immunization Safety Review Committee
meeting. Pressing forward with this meeting at this time, I believe, will
further undermine the credibility of the Centers for Disease Control (CDC)
on matters of vaccine safety and do damage to the reputation of the IOM. I
believe the proposed date of this meeting, which you have the ability to
change, is in the best interests of no one who is seeking the truth about a
possible association between vaccines and neurodevelopmental disorders,
including autism… Additionally, I am concerned that the agenda set forth in
the meeting is inadequate and incomplete. With respect to the MMR/autism
concerns, the IOM is dedicating one hour. Two witnesses are woefully
inadequate to update the committee on the research to date. The time set
aside for a discussion of epidemiology relating to thimerosal and autism is
heavily biased against those who have raised these concerns and will not
allow for a fair and balanced discussion of the literature. The time set
aside for a discussion of the biological mechanisms of thimerosal and autism
is inadequate to allow a full discussion of the issue. To consider two
issues of such significance in only seven hours does not serve the public
interest. To the outside observer it does not appear to be a serious effort
to examine these critical issues. Any conclusions drawn from this meeting,
including any report issued, will be viewed as suspect given the very
limited time dedicated to examining very incomplete information.”
Dr. Gerberding responded that she had shared Dr. Weldon's concerns with IOM
President, Dr. Harvey V. Fineberg but that the meeting will be held as
planned. She wrote: “My own view is that it is extremely important to have
the IOM conduct an objective review of emerging data when it has a bearing
on vaccine safety as quickly as possible. In addition, the process should
be ongoing at regular intervals, to keep up with this science of vaccine
safety as new information becomes available. We intend to renew our
agreement with the IOM to ensure continuation of the safety review process.”
(7)
The Immunization Safety Review Committee meeting of February 9, 2004
At the meeting (8, 9), Dr. Weldon who spoke first remarked: “This
atmosphere of intimidation even surrounds today's hearing. I received
numerous complaints that this event is not a further attempt to get at the
facts but rather a desire to sweep these issues under the rug. I have the
utmost respect for the Institute and the Academy nonetheless I shared these
concerns with Dr. Gerberding. Last week she called me to assure me that
this is not the case. She informed me that she wants to meet with me and
some of the parents, clinicians, and researchers to work with them to get
the proper answers."
The Congressman was followed by Mady Hornig MD, Mark R. Geier, M.D., Ph.D.,
H. Vasken Aposhian, Ph.D., David Baskin, M.D., Boyd Haley, Ph.D., Jeff
Bradstreet, M.D., FAAFP and Vijendra K. Singh, Ph.D. who presented research
supporting a vaccine-autism connection. Dr. Andrew Wakefield was not
invited.
The Report
The report of the meeting was released in May 2004.
The following is from the May 18, 2004 press release (10) “MMR Vaccine and
Thimerosal-Containing Vaccines Are Not Associated With Autism, IOM Report
Says” in the National Academies News: “Based on a thorough review of
clinical and epidemiological studies, neither the mercury-based vaccine
preservative thimerosal nor the measles-mumps-rubella (MMR) vaccine are
associated with autism, says a new report from the Institute of Medicine of
the National Academies. Furthermore, the hypotheses regarding how the MMR
vaccine and thimerosal could trigger autism lack supporting evidence and are
theoretical only. Further research to find the cause of autism should be
directed toward other lines of inquiry that are supported by current
knowledge and evidence and offer more promise for providing an answer.”
In other words, according to the committee, both MMR-autism and
Thimerosal-autism research should be abandoned, because they are based on
unsupported hypothetical theories, and any future autism research should be
directed elsewhere and never again to the MMR/Thimerosal and autism
connection.
In the press release, Marie McCormick MD, Chair of the Committee was quoted
as saying: “The overwhelming evidence from several well-designed studies
indicates that childhood vaccines are not associated with autism."
In an interview, Dr. McCormick also claimed that “The weight of that
evidence is pretty substantial"(11)
In a similar situation in 2001, Dr. McCormick stated “It [MMR] is as safe as
a vaccine can get” when the Immunization Safety Review Committee “did not
exclude the possibility that MMR vaccine could contribute to ASD in a small
number of children”. Her comments then prompted Walter O. Spitzer, MD,
Emeritus Professor of Epidemiology at McGill University to write: “As an
epidemiologist who has been a Member of the IOM since 1986 … I am
embarrassed by the process of this latest Report and would urge President
Shine of the IOM to retract the Report until the message has been clarified.
What was released, the IOM Report or the McCormick Position?” (12)
On May 29, 2004, Dr. Weldon criticized the conclusions of the February 9
meeting and the fact that they were not based on biological evidence but
mostly on epidemiological studies by Verstreaten, Hviid, Madsen, Stehr-Green
and Miller. He then went on to enumerate the multiple limitations and
deficiencies of each of the five studies. (13)
A year later, it is evident that Dr. Weldon was correct and that Dr
McCormick's “overwhelming evidence” and “well-designed studies” have
crumbled. In addition, the findings of the Madsen MMR study were challenged
(14-15) and several other epidemiological studies exonerating Thimerosal and
the MMR vaccine were effectively neutralized shortly after they were
published.
Meanwhile, extensive biological research has taken place. The animal studies
by Hornig (16) have been supported by those of Burbacher (17) and other
solid and reliable thimerosal studies have been published (18-28).
Wakefield's research has been widely duplicated and many more children with
autism have been found to have evidence of measles virus genomic RNA in the
blood and cerebrospinal fluid (29, 30) with elevated levels of myelin basic
protein autoantibodies.
A significant number of children have exhibited two autistic regressions:
one after their initial MMR vaccination and the second after their MMR
booster following a period of relative improvement. This Challenge-Dechallenge-Rechallenge
was accepted by the IOM as evidence of causation in 1991 in a case of
recurrent hemolytic anemia following DPT vaccinations. It was also discussed
in detail in a subsequent IOM report in 1994 entitled “Adverse Events
Associated with Childhood Vaccines. Evidence Bearing on Causality.”
Considering all of the above, the available evidence does not favor
rejection of a causal relation between Thimerosal or MMR and autism spectrum
disorders.
Official Request
I respectfully request that President Harvey V. Fineberg, MD, PhD:
o
Withdraw
the report of the Immunization Safety Review Committee Meeting 9 of February
9, 2004
o
Form a
new committee under a new chairman all of whom should be impartial experts
independent of influence of Government and pharmaceutical companies.
o
Reconvene a meeting on vaccines and autism as soon as possible and ensure
that all independent research is considered.
By supporting this request, Director Gerberding can prove that she really
meant to work with parents, clinicians, and researchers to get the proper
answers.
References:
1.
http://www.ideadata.org/tables26th/ar_aa3.htm
2.
http://www.ideadata.org/tables27th/ar_aa3.htm
3.
http://www.ideadata.org/tables26th/ar_aa2.htm
4.
http://www.ideadata.org/tables27th/ar_aa2.htm
5.
American
Academy of Pediatrics, Center for Disease Control's National Center on Birth
Defects and Developmental Disabilities. 2004. Autism A.L.A.R.M. http://www.medicalhomeinfo.org
http://www.medicalhomeinfo.org/screening/Autism%20downloads/AutismAlarm.pdf
6.
http://www.nationalautismassociation.org/grassroots12204.php
7.
Reference available on request
8.
http://www.iom.edu/subpage.asp?id=18065
9.
http://www.partnersforimmunization.org/meetingupdates_vac2904.html
10.
http://www.iom.edu/report.asp?id=20155 (Press Release)
11.
http://www.medicalnewstoday.com/medicalnews.php?newsid=8551
12.
http://www.mindfully.org/Health/Autism-Mercury-Vaccine.htm
13.
http://autismone.org/AutismOne2004/presentations/Weldon%20Dave,%20Congressman,%20MD.pdf
14.
Goldman
GS, Yazbak FE: An Investigation of the Association between MMR Vaccination
and Autism in Denmark. JAmPhysSurg 2004; 9(3):70-75
http://www.jpands.org/vol9no3/goldman.pdf
15.
Stott C,
Blaxill M, Wakefield AJ: MMR and Autism in Perspective: The Denmark Story.
JAmPhysSurg 2004; 9(3):89-91
http://www.jpands.org/vol9no3/stott.pdf
16.
Hornig M, Chian D, Lipkin WI. Neurotoxic effects of postnatal thimerosal
are mouse strain dependent. Mol Psychiatry. 2004 Sep;9(9):833-45
17.
Burbacher TM, Shen DD, Liberato N, Grant KS, Cernichiari E, Clarckson T.
Comparison of Blood and Brain Mercury Levels in Infant Monkeys Exposed
to Methylmercury or Vaccines Containing Thimerosal
.http://ehp.niehs.nih.gov/members/2005/7712/7712.pdf
18.
Waly M,
Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, Sukumar S, Shim S,
Sharma A, Benzecry JM, Power-Charnitsky VA, Deth RC. Activation of
methionine synthase by insulin-like growth factor-1 and dopamine: a target
for neurodevelopmental toxins and thimerosal. Mol Psychiatry. 2004
Apr;9(4):358-70.
19.
James
SJ, Slikker W 3rd, Melnyk S, New E, Pogribna M, Jernigan S. Thimerosal
neurotoxicity is associated with glutathione depletion: protection with
glutathione precursors. Neurotoxicology. 2005 Jan;26(1):1-8.
20.
Geier
DA, Geier MR. A comparative evaluation of the effects of MMR
immunization and mercury doses from thimerosal-containing childhood vaccines
on the population prevalence of autism.Med Sci Monit. 2004 Mar;10(3):PI33-9.
21.
Geier
D, Geier MR. Neurodevelopmental disorders following
thimerosal-containing childhood immunizations: a follow-up analysis.
Int J Toxicol. 2004 Nov-Dec;23(6):369-76.
22.
Geier
DA, Geier MR. A two-phased population epidemiological study of the safety of
thimerosal-containing vaccines: a follow-up analysis. Med Sci Monit. 2005
Mar 24;11(4):CR160-170
23.
Blaxill
MF, L Redwood L, and Bernard S.Thimerosal and autism? A plausible hypothesis
that should not be dismissed. Medical Hypotheses; 62: 788-794, 2004.
24.
Humphrey
ML, Cole MP, Pendergrass JC, Kiningham KK. Mitochondrial Mediated
Thimerosal-Induced Apoptosis in a Human Neuroblastoma Cell Line (SK-N-SH).
Neurotoxicology. 2005 Apr 30; [Epub ahead of print]
25.
Parran
DK, Barker A, Ehrich M. Effects of Thimerosal on NGF signal transduction and
cell death in neuroblastoma cells Toxicol Sci. 2005 Apr 20; [Epub ahead of
print]
26.
Havarinasab S, Haggqvist B, Bjorn E, Pollard KM, Hultman P.
Immunosuppressive and autoimmune effects of thimerosal in mice. Toxicol Appl
Pharmacol. 2005 Apr 15;204(2):109-21.
27.
Ueha-Ishibashi T, Tatsuishi T, Iwase K, Nakao H, Umebayashi C, Nishizaki Y,
Nishimura Y, Oyama Y, Hirama S, Okano Y. Property of thimerosal-induced
decrease in cellular content of glutathione in rat thymocytes: a flow
cytometric study with 5-chloromethylfluorescein diacetate.Toxicol In Vitro.
2004 Oct;18(5):563-9
28.
http://www.ewg.org/reports/autism/execsumm.php
29.
Bradstreet JJ, El Dahr J, Anthony A, Kartzinel JJ, Wakefield AJ. Detection
of measles virus genomic RNAin cerebrospinal fuild of children with
regressive autism: a report of three cases. JAmPhysSurg 2004; 9(2):38-45
http://www.jpands.org/vol9no2/bradstreet.pdf
30.
http://www.icdrc.org/executive_briefing.html
________________________________
F.
Edward Yazbak, MD, FAAP
TL Autism Research
Falmouth, Massachusetts, 02540
http://www.taap.info/Fineberg.pdf
Go Top